The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1549
A New Amphetamine Oral Suspension (Adzenys ER) for ADHD (online only)
The full article is available to subscribers Subscriber Login   

The FDA has approved an extended-release oral suspension formulation of amphetamine (Adzenys ER – Neos) for treatment of attention deficit hyperactivity disorder (ADHD) in patients ≥6 years old. The same extended-release amphetamine product is available as an orally disintegrating tablet and is marketed as Adzenys XR-ODT. Another extended-release oral suspension formulation of amphetamine, Dyanavel XR, was approved earlier.1

STIMULANTS — Stimulant medications are usually prescribed first for treatment of children with ADHD.2,3 Amphetamines have generally been as effective as methylphenidate in decreasing overactivity, impulsivity, and inattention. Some children who have not responded to methylphenidate may respond to an amphetamine, and vice versa.4

THE ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: A New Amphetamine Oral Suspension (Adzenys ER) for ADHD (online only)
Article code: 1549f
 Electronic, downloadable article - $25